Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating retinal neovascular diseases

A new blood vessel and retinal technology, applied in cardiovascular system diseases, sensory diseases, drug combinations, etc., can solve the problem of inconclusive complement components

Inactive Publication Date: 2012-10-24
SHANDONG EYE INST
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among them, the participation of inflammation and complement pathways has been confirmed in some retinal neovascular diseases, but the specific process and the involved complement components are still inconclusive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Nafamostat mesylate added with C3a antibody

[0042] C3a antibody was purchased from Abcam (ab48581). The prepared medicine contains nafalimus mesylate with a mass volume ratio g / ml of 2%, and at the same time, C3a antibody with a mass volume ratio g / ml of 0.002% is added, and the preservative phenylethyl alcohol is added at a mass volume ratio of g / ml was 1.1%, and finally supplemented to the final volume with phosphate buffered saline.

[0043] The dosages of nafalimus mesylate, antibodies and preservatives are based on the pharmacological dosages, and those skilled in the art can determine the dosages by conventional methods, and are not limited to the scope described in the specification of the present invention.

[0044] The specific preparation method is to dissolve nafamostat mesylate solid powder in phosphate buffer solution (9 grams of sodium chloride, 6 grams of disodium hydrogen phosphate, 0.4 grams of sodium dihydrogen phosphate, add double dist...

Embodiment 2

[0045] Example 2: Nafamostat mesylate added C3a and C5a antibodies

[0046] C5a antibody was purchased from Santa Cruz Company (sc-21941). Add 1 g of nafalimus mesylate to 90 ml of phosphate buffer, then add 0.003 g of a mixture of C3a and C5a antibodies, where the ratio of C3a and C5a antibodies is 1:1, and then add 1 g of preservative phenylethanol as a preservative agent, and finally filled to 100ml with phosphate buffered saline.

[0047] The C3a and C5a antibodies can be added in equal proportions, or any pharmacologically acceptable proportion can be selected.

[0048] According to the intraperitoneal administration dose of nafamostat mesylate 50mg / kg, since the P12 day of the oxygen induction model, the medicine prepared in this embodiment 2 is injected every day, and it can be observed at P17 where the growth of retinal neovascularization is the most vigorous. The growth of retinal neovascularization in mice treated with the drug of this example is more effective and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for treating retinal neovascular diseases, which is prepared from nafamostat mesylate; moreover, antibodies of endotoxin molecules C3a and / or C5a of a complement system are selectively added in the medicine. According to the invention, the nafamostat mesylate is used for preparing the medicine for treating retinal neovascular diseases, wherein the nafamostat mesylate acts on complement way; in addition, antibodies of C3a and C5a polypeptides are added to the medicine to generate neutralization; therefore, the growth of retinal neovascular can be controlled more effectively. The prepared medicine can be a novel medicine for treating retinal neovascular diseases, thereby providing a new thought for clinically treating various retinal neovascular diseases.

Description

technical field [0001] The invention belongs to the technical field of biological prevention and treatment of fundus diseases, and specifically relates to a new application of Nafamostat mesylate (FUT-175), a drug for treating retinal neovascular diseases, and the use of mesylate The nafamostat is prepared as a main raw material, and is used for treating retinal neovascular diseases. Background technique [0002] Retinal neovascular disease is one of the most serious blinding eye diseases in my country and even in the world. It mainly refers to blinding vitreoretinal disease caused by pathological changes such as hemorrhage, exudation, and proliferation of new blood vessels. Including diabetic retinopathy, retinal vascular occlusive disease, retinal periphlebitis, retinopathy of prematurity, etc., the threat to the visual health of the Chinese population has become increasingly prominent. For a long time, there have been different opinions on the mechanism of retinal neovas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/245A61K39/395A61P9/10A61P27/02
Inventor 朱玮祁霞贾玉东
Owner SHANDONG EYE INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com